Acrivon Therapeutics, Inc. Common StockACRVNASDAQ
Loading
SG&A Expenses Over TimeStrong
Percentile Rank80
3Y CAGR+40.4%
5Y CAGR+79.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+40.4%/yr
Annual compound
5Y CAGR
+79.4%/yr
Recent deceleration
Percentile
P80
Within normal range
vs 5Y Ago
18.6x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
TTM$24.12M-4.3%
2024$25.21M+18.8%
2023$21.21M+143.6%
2022$8.71M+253.1%
2021$2.47M+90.0%
2020$1.30M-